Pearl Diagnostics, Inc.

Funding and NIH signals

• SEC Form D raise Raised $11.15M (Form D filed Apr 21, 2026). SEC Form D 0001922830-26-000003 (Apr 21, 2026)
  Evidence (1 event)

  • Apr 21, 2026 · SEC Form D 0001922830-26-000003
    Name of Issuer: Pearl Diagnostics, Inc.; CIK: 1922830; Address: Baltimore, MD; Submission type: D; Filing date: 2026-04-21; Industry Group: Biotechnology; Date of First Sale: 2026-03-19; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 11150000; Total Amount Sold: 11150000; Federal exemptions: 06b
• NIH award NIH awarded $977K (SBIR commercialization 5SB1AI186689-02, continuation, notice Jun 30, 2026). NIH RePORTER 5SB1AI186689-02 (Jun 30, 2026)
  Evidence (1 event)

  • Jun 30, 2026 · NIH RePORTER 5SB1AI186689-02
    Organization: PEARL DIAGNOSTICS, INC.; City/State: BALTIMORE, MD; Project number: 5SB1AI186689-02; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-06-30; FY total cost (award amount): 977071; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: A Point of Care Urine Test to Aid Diagnosis of Aspergillosis; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals